
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 20, 2026, 1:10 PM ET
H.C. Wainwright lowers Savara price target to $9 from $10, keeps Buy rating
Nasdaq: $SVRABiotech · rare lung diseaseFDA review continuingNo product revenueU.S. action undated
SVRA Stock Hub: Savara News, MOLBREEVI and the FDA Review
The U.S. review of Savara’s sole drug candidate continues without a new action date. On November 20, 2026, the company said the FDA would miss its November 22 target for molgramostim in autoimmune pulmonary alveolar proteinosis (PAP). Savara ended September with $129.6 million in cash and short-term investments, after using $105.3 million in operations over nine months. The timing of a potential approval matters for both the launch and the company’s access to conditional funding. Savara, November 20, 2026 Form 10-Q, September 2026
Full research report · PDF
Savara ($SVRA) Research updated November 19, 2026
23 pages: the autoimmune PAP disease background, the IMPALA-2 results and the long-term open-label data, the regulatory history from the March 2025 filing to the November 22, 2026 target date under the Prescription Drug User Fee Act (PDUFA), the third-quarter 2026 statements, cash and burn, the Hercules facility and the RTW royalty, shares, pre-funded warrants and awards, ownership and short interest, risks and sources. Available in the Merlintrader Research Library. For personal use only: redistribution prohibited.
Next catalyst
FDA review of molgramostim for autoimmune PAP · no revised date
Savara said the FDA will miss the November 22, 2026 target action date for the molgramostim biologics license application (BLA). The FDA’s review continues, and the company said the agency had given no revised action date. Savara, November 20, 2026
March 31, 2027 is the RTW deadline for qualifying FDA approval. The other closing conditions and the separate Hercules borrowing window are explained in chapter 10. Form 10-Q, September 2026
SVRA stock at a glance
Chart analysis · JC
Technical chart analysis of $SVRA with bull and bear scenarios on JC Just Charts.
Cash + short-term · Sep 30
$129.6M
$29.8M of cash and $99.8M of short-term investments, against $173.0M at June 30 and $235.7M at December 31, 2025. Form 10-Q, September 2026 Form 10-Q, June 2026
Operating expenses · Q3
$43.5M
$24.9M of research and development and $18.5M of general and administrative expenses, the latter up 93% year on year. Net loss was $43.0M, or $0.17 a share, with no product revenue. Form 10-Q, September 2026
Operating cash use · 9 months
$105.3M
Against $76.0M in the first nine months of 2025; $42.5M of it in the September quarter alone (Merlintrader calculation). Form 10-Q, September 2026 Form 10-Q, June 2026
Shares outstanding · Nov 9
220.6M
205,536,152 at September 30 and 220,623,511 at November 9; the quarter’s weighted-average loss-per-share denominator was 254.2 million shares, including qualifying pre-funded warrants. Form 10-Q, September 2026
Short interest · Oct 30
32.3M
Reported shares short, with 12.9 days to cover at the published average volume. Nasdaq short interest
Conditional funding capacity
Up to $150M
$75M royalty advance with a March 31, 2027 cutoff for qualifying FDA approval. Up to $75M of secured term loans under separate conditions. See chapter 10. Form 10-Q, September 2026
Where Savara stands now
Savara’s immediate job is to sustain the molgramostim program while the FDA continues its review. The application covers an inhaled biologic for autoimmune PAP, Savara’s only program. The November announcement changed the timetable investors had been following and left the outcome open. Savara, November 20, 2026 Form 10-Q, September 2026
The regulatory file has passed through an initial refusal to file, resubmission with a different named manufacturer, acceptance for Priority Review and an extension last April. Chapter 07 traces those steps. The latest communication gives no reason for the agency’s current timing. Form 10-K, 2025 Form 10-Q, September 2026 Savara, November 20, 2026
The most recent financial statements describe a business already paying for commercial preparation. The Q3 filing shows higher personnel and operating costs alongside the spending on molgramostim. Chapter 09 links the expense trend to the decline in liquid resources. Form 10-Q, September 2026
Review timing now drives financing risk. The company’s two additional sources of capital depend on approval and carry separate conditions. A later decision can change when funds are available and whether the current royalty terms still provide an upfront payment. Form 10-Q, September 2026 Savara, November 20, 2026
▲ The constructive case
The pivotal trial showed a placebo-adjusted improvement in pulmonary gas transfer, and Savara already selected a U.S. specialty pharmacy. FDA approval could allow Savara to proceed with a commercial launch. The RTW advance and Hercules draws would depend on the separate conditions in chapter 10. Trapnell et al., NEJM 2025 Savara and PANTHERx Rare, January 2026 Form 10-Q, September 2026
▼ The cautious case
An open-ended review extends the period in which operations are funded from existing resources or alternative financing. Savara would have to reassess the timing of its preparations if the review runs past the date that governs the RTW payment. The reported cost base gives that possibility practical weight. Savara, November 20, 2026 Form 10-Q, September 2026
Latest Savara news
Nov 20, 2026
H.C. Wainwright lowers Savara price target to $9 from $10, keeps Buy rating
H.C. Wainwright cut its price target on Savara to $9 from $10. The firm kept its Buy rating on the stock.
Nov 20, 2026
Savara Informed FDA Will Not Act on Molgramostim BLA by PDUFA Date
Savara announced that the FDA has communicated it will not meet the PDUFA target action date of November 22, 2026, for the molgramostim inhalation solution BLA for autoimmune PAP. The review of the BLA is ongoing, and the agency has not provided a revised action date. Chair and CEO Matt Pauls said the company looks forward to working closely with the agency to complete its review.
Nov 12, 2026
Savara Announces New Employment Inducement Grant
On November 10, 2026, the Compensation Committee of Savara's Board of Directors granted inducement awards to seven new employees. The awards include options to purchase 20,500 shares at an exercise price of $4.92 per share, RSUs covering 38,500 shares, and PSUs covering 8,000 shares. The grants were made under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Nov 12, 2026
H.C. Wainwright reinstates Savara coverage with Buy rating and $10 price target
H.C. Wainwright resumed coverage of Savara with a Buy rating and a price target of $10. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Oct 21, 2026
CHEST 2026 poster: post-hoc IMPALA analysis in aPAP patients with mildly reduced or normal diffusing capacity
Savara presented a post-hoc analysis of the Phase 2/3 IMPALA trial in autoimmune PAP patients with baseline hemoglobin-adjusted DLco% above 70%: 13 of 138 randomized patients, of whom 8 on once-daily molgramostim and 3 on placebo were analyzed (2 on the intermittent regimen were excluded); 7 of the 8 molgramostim patients had complete Week 24 data. With molgramostim the mean alveolar-arterial oxygen gradient fell from 32.5 to 19.8 mmHg at Week 24 (−12.7 mmHg) versus −0.3 mmHg on placebo; the SGRQ activity score fell by 11.1 points versus 2.3, the total score by 7.8 versus 7.2, and the chest-CT ground-glass score by 4.9 points versus an increase of 0.2. DLco% was maintained. The company states that, given the small number of patients, all findings are descriptive, exploratory and hypothesis-generating. Company release →
Oct 12, 2026
CHEST 2026: encore oral on long-term IMPALA-2 data and a new IMPALA analysis
Savara will present at CHEST 2026 in Phoenix (October 18–21). An encore oral presentation covers long-term efficacy and safety of molgramostim in autoimmune PAP from the open-label treatment period of the Phase 3 IMPALA-2 trial, on Tuesday, October 20, 2026, 1:45–2:30 PM MST. A poster on molgramostim treatment effects in aPAP patients with mild diffusion impairment, a new analysis of the Phase 2/3 IMPALA trial, follows on Wednesday, October 21, 10:20–11:05 AM MST. Both are presented by Bruce C. Trapnell, M.D., of the University of Cincinnati, who also speaks with two patients at a company learning theatre on aPAP on October 20. The oral repeats previously presented long-term data; neither presentation is a regulatory decision. Company release →
SVRA stock catalysts: the dated calendar
- May 2019 / December 2019 — FDA granted Fast Track and Breakthrough Therapy designations for molgramostim in autoimmune PAP. Completed · Form 10-K, 2025
- March 26, 2025 — Savara completed the original rolling BLA submission. Completed · Form 10-K, 2025
- May 2025 — Savara received a Refusal to File letter for the original application. Completed · Form 10-K, 2025
- December 2025 — Savara resubmitted the BLA with FUJIFILM Diosynth as the drug-substance manufacturer and requested Priority Review. Completed · Form 10-K, 2025
- January 8, 2026 — Savara selected PANTHERx Rare as its exclusive U.S. specialty pharmacy for MOLBREEVI. Completed · Savara and PANTHERx Rare, January 2026
- January 26, 2026 — The Hercules amendment provided for post-approval term loans, subject to the agreement. Completed · Form 8-K, January 2026
- February 2026 — The FDA accepted the resubmission for review and granted Priority Review. Completed · Form 10-Q, September 2026
- March 10, 2026 — Savara signed its Yardley headquarters lease. Completed · Form 8-K, March 2026 headquarters lease
- March 2026 — The European Medicines Agency validated the European marketing application. Completed · Form 10-Q, September 2026
- April 2026 — The Medicines and Healthcare products Regulatory Agency (MHRA) validated the U.K. application for accelerated review. Completed · Form 10-Q, September 2026
- April 15, 2026 — Savara announced that the FDA had extended the review by three months to November 22, 2026, after a major amendment. Completed · company release
- June 4, 2026 — Shareholders approved an increase to 600 million authorized common shares and an amendment to the 2024 equity plan. Completed · Form 8-K, June 2026
- June 8, 2026 — Savara announced that Robert Lutz, then chief operating officer, would add the chief financial officer role on July 15, 2026, when David Lowrance stepped down as chief financial and administrative officer. Completed · Form 8-K, June 2026
- July 30, 2026 — Savara announced European and Australian patents for the liquid formulation through March 2041. Completed · Savara, July 2026 patent announcement
- May to October 2026 — Molgramostim conference updates included IMPALA-2 follow-up and a post hoc analysis from the earlier IMPALA trial. Conference updates · IMPALA-2 open-label results, ATS 2026 conference abstract · Savara, ERS congress update, August 2026 · Savara, CHEST presentation, October 2026
- November 9, 2026 — Third-quarter report: $129.6 million of liquidity, $43.0 million net loss, $105.3 million of operating cash use in nine months. Completed · Form 10-Q
- Next FDA update · undated — The FDA’s molgramostim review continues. On November 20, Savara said the FDA would miss the former November 22, 2026 PDUFA target and had given no replacement date. Pending · Savara, November 20, 2026
- Fourth quarter of 2026 — Savara’s August 2026 guidance for a U.K. decision after the MHRA’s accelerated review. Company expectation · Savara, August 11, 2026 Q2 results
- First quarter of 2027 — Savara’s August 2026 guidance for a decision on the European application. Company expectation · Savara, August 11, 2026 Q2 results
- March 31, 2027 — Deadline for qualifying FDA approval under the $75 million RTW agreement. Other closing conditions apply. See chapter 10. Contractual · Form 10-Q, September 2026 · RTW purchase and sale agreement, SEC exhibit
- May 30, 2027 — Estimated IMPALA-2 study completion, including long-term follow-up. Registry estimate · ClinicalTrials.gov, NCT04544293
- June 30, 2027 — Outside deadline for draws of the post-approval Hercules tranches. The period ends earlier if 120 days from the contractually defined Approval Milestone elapse first. Contractual · Form 10-Q, September 2026 · Hercules first amendment, SEC exhibit
- After approval — Under the RTW agreement, royalties begin in the first calendar quarter with a U.S. commercial sale if its closing conditions have been met. Conditional, undated · Form 10-Q, September 2026 · RTW purchase and sale agreement, SEC exhibit
The MOLBREEVI program at a glance
| Item | Detail |
|---|---|
| Product | Molgramostim inhalation solution, proposed trade name MOLBREEVI: non-glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), 300 µg in 1.2 mL, once daily by inhalation. Form 10-K, 2025 Trapnell et al., NEJM 2025 |
| Device | PARI eFlow Nebulizer System, developed for this formulation; nebulization time of about 3 to 5 minutes; handset replaced monthly. Form 10-K, 2025 Savara corporate overview, January 2026 SEC exhibit |
| Indication | Autoimmune pulmonary alveolar proteinosis, the most common cause of PAP in the Japanese national cohort. Inoue et al., AJRCCM 2008 |
| Pivotal trial | IMPALA-2 randomized 164 patients. The 48-week double-blind period was followed by a 96-week open-label period. Trapnell et al., NEJM 2025 ClinicalTrials.gov, NCT04544293 |
| Primary endpoint | Week 24 change in hemoglobin-adjusted diffusing capacity for carbon monoxide (DLCO) as a percentage of the predicted value: 9.8 percentage points with molgramostim and 3.8 with placebo, an estimated difference of 6.0 points (P < 0.001). Trapnell et al., NEJM 2025 |
| Regulatory status | U.S. review continues, no replacement date disclosed as of November 20. EU and U.K. applications are separate. Savara, November 20, 2026 Form 10-Q, September 2026 |
| Manufacturing | FUJIFILM Diosynth for drug substance, Patheon for drug product, PARI for the device, all outsourced. Form 10-K, 2025 |
| Exclusivity | MOLBREEVI has orphan drug designation in the U.S. and EU. A qualifying approval can confer seven years of U.S. orphan drug exclusivity or up to ten years of EU orphan market exclusivity for the approved indication. Separate U.S. biologics exclusivity may apply for 12 years after first licensure. Form 10-K, 2025 |
| Patents | Drug-device combination patent in Europe to March 2043; liquid formulation patents in Europe and Australia to March 2041. Savara, July 2026 patent announcement |
Who the patients are, and how small the market is
The Japanese observational cohort found that autoimmune disease accounted for 89.9% of the PAP cases it captured. Investigators estimated minimum incidence of 0.49 per million per year and minimum prevalence of 6.2 per million. Those estimates describe the Japanese population and the study’s ascertainment. They provide a scale for the disease without prescribing a patient count for a U.S. launch. Inoue et al., AJRCCM 2008
Prevalence measures the people living with the disease in a population. A commercial estimate would have to address diagnosis, eligibility under any approved label, treatment need, access and ongoing use. Those transitions would determine how many people start and continue the product. Savara’s filings describe the preparatory work for a launch, while sales and a realized price would require an authorized product in commercial use. Form 10-Q, September 2026 Form 10-K, 2025
A second consideration is how patients reach expert care. The European Respiratory Society guidance describes imaging and bronchoalveolar lavage as part of the pathway to diagnosing PAP, with GM-CSF antibody testing helping establish the autoimmune cause. The market therefore begins with finding and classifying a rare disease. That is a different challenge from supplying patients once they have a diagnosis and a plan of treatment. McCarthy et al., European Respiratory Journal 2024
Savara deep dive: the full analysis
The Merlintrader Research Library collects our dated biotech stock research reports.
01 Three scenarios: approval is also the funding event
Bull case — approval within the funding window and a broad label
Savara could receive a revised FDA timetable before a decision. A qualifying FDA approval within the royalty agreement’s window would preserve eligibility for the upfront payment, subject to the other closing conditions. Once an approved label exists, the breadth of the indication, the conditions of use and any required follow-up would help define the commercial opportunity. The financial package would still contain two very different instruments: an advance paid for a share of future sales and a secured credit facility with a draw window. Savara, November 20, 2026 Form 10-Q, September 2026
A broad label would give Savara a larger starting population within its intended indication. Treatment decisions would still take place at centers familiar with autoimmune PAP, and some patients would have been managed by observation or lavage. The randomized trial provides a rationale for offering a disease-directed inhaled treatment to appropriate patients. A broad label would leave room for physicians and payers to determine where that treatment fits. The central commercial question would shift from availability of the medicine to the speed at which patients can actually start and continue it. Trapnell et al., NEJM 2025 McCarthy et al., European Respiratory Journal 2024
The first signs of a funded launch would be transactions and operating milestones: the royalty proceeds appearing in cash, any Hercules borrowing reported separately, and the timing of commercial availability. After first sale, useful measures would include actual product revenue, distribution costs and support for the cadence of patient starts. The relevant test is whether the company converts an authorization into commercial activity while preserving enough capital to serve a small, geographically dispersed population. Form 10-Q, September 2026 Savara and PANTHERx Rare, January 2026
Base case — eventual approval and a gradual launch
A middle path would combine eventual FDA approval with slower adoption, tighter access or extra commercialization spending. The specialty pharmacy can provide a single channel for distribution, while enrollment and reimbursement decisions can still make the timeline from prescription to start uneven. A quarter with small sales could therefore coexist with a product that is gaining interest. Operational cash use would continue during this transition, and the cost of running the company would remain visible sooner than the scale of its recurring revenue. Form 10-Q, September 2026 Savara and PANTHERx Rare, January 2026
The middle case is sensitive to the calendar even if the outcome is favorable. An approval nearer the end of the draw window gives management less time to decide when to draw secured debt. A qualifying FDA approval by the royalty deadline could preserve eligibility for the advance. Commercial sales would follow their own timetable. Once sales begin, the royalty mechanics depend on net sales and can affect the early revenue retained by Savara. Royalty proceeds, loan draws and product revenue may arrive at different times. Form 10-Q, September 2026
A narrower label could introduce a second commercial constraint. The relevant distinction would be between the patients represented in the full clinical data set and those included in the approved indication. Any limits involving age, disease status, or use of the drug and device would be readable only in the eventual label. A subgroup analysis disclosed by the company can help frame questions about evidence at different levels of impairment. The subgroup findings themselves leave the eventual scope of authorization open, and a sales scenario that presumes inclusion would be speculative. Trapnell et al., NEJM 2025 Savara, CHEST presentation, October 2026
Bear case — a prolonged review or loss of contracted funding
The adverse path includes a prolonged review, a complete response letter, or an eventual approval that arrives outside the original RTW window. Those outcomes differ in regulatory meaning and may require very different operating decisions. A missed agency target has already created schedule uncertainty. A complete response letter, if one is issued, would bring a distinct set of questions about the deficiencies the FDA identifies and the work required for another submission. A late approval could allow a launch while leaving the company with less contracted funding under the current terms. Savara, November 20, 2026 Form 10-Q, September 2026
Operating flexibility would matter most on that path. Savara could carry commercial preparation costs for longer before sales begin, curtail spending, or seek financing from other sources. None of those actions follows automatically from the November announcement. The next periodic filing would show what happened to working capital, vendor commitments and the pace of expense. A useful comparison would be with cash used by operations during Q3, alongside the change in cash and investments and any financing actually raised. Form 10-Q, September 2026
A more difficult outcome can also follow formal approval. If timing compresses the financing window and a label or postmarketing requirement increases the cost of deployment, the company might face several demands on cash at once. It would have to choose which spending is required to make the approved product available and how much capital to add before reliable demand data arrive. Keeping these operational questions separate from the original clinical result makes it possible to assess the business once the FDA provides a decision or another substantive update. Savara, November 20, 2026 Form 10-Q, September 2026
What could change this assessment
The central thesis is that a positive trial result already exists, while the date on which the company could put the drug into U.S. distribution and unlock conditional financing has become less predictable. The outlook would change if Savara announced a revised FDA timetable with a defined decision window, replaced or extended the financing arrangements, or demonstrated that its operating requirements had fallen materially. The items below identify public developments that could alter that reading. Savara, November 20, 2026 Form 10-Q, September 2026
- A dated FDA update. A new target would narrow the open timing question and give Savara a clearer reference point for deployment. Savara, November 20, 2026
- A change to the royalty contract. An extension or a replacement source of funding would change the importance of March 31. Form 10-Q, September 2026
- A materially different rate of cash use. Spending that falls or accelerates would change the time available under the September starting balance. Form 10-Q, September 2026
- A label that materially changes eligible use. The indicated population and treatment conditions would determine how closely launch plans match the trial population. Trapnell et al., NEJM 2025
- Actual launch and funding receipts. Cash, draws and first sale would turn three contingent pieces of the scenario into measurable events. Form 10-Q, September 2026
02 What Savara does: one inhaled biologic for one rare lung disease
Savara develops a single investigational program, molgramostim inhalation solution, for autoimmune pulmonary alveolar proteinosis. Its quarterly filing describes it as a rare respiratory disease company and identifies MOLBREEVI as the proposed trade name for the program. That focus means the same molecule accounts for the principal regulatory effort, manufacturing investment and planned commercial infrastructure. Form 10-Q, September 2026
GM-CSF is the therapeutic class. Molgramostim is a particular recombinant formulation under review for administration by inhalation with a dedicated nebulizer. Another recombinant GM-CSF, sargramostim, has been evaluated in a distinct randomized study in autoimmune PAP. The difference between a class and a product matters to the business because a trial of one formulation can support the therapeutic rationale without defining the other formulation’s benefit, labeling or delivery requirements. The commercial package would be tied to the product described in Savara’s filing and the final terms of any authorization. Form 10-K, 2025 Tazawa et al., NEJM 2019
The nebulizer is part of the operating proposition. Commercial distribution would bring the medicine and its administration system together after approval. Savara separately provides investigational access to eligible patients in select countries. Savara’s agreement with PARI is therefore part of product economics and fulfillment as well as clinical development. Consistent access to both components would matter after launch, especially if patients are expected to administer treatment themselves and need a regular supply of replacement components. Form 10-K, 2025
The selected U.S. specialty pharmacy, PANTHERx Rare, gives Savara a defined channel for fulfillment if molgramostim is authorized. The announced arrangement involves a specialty provider in a market organized around relatively few patients. The presence of a partner can reduce the commercial tasks a small sponsor must handle directly, while the issuer remains responsible for bringing a viable product to market. Selection of a channel came before an authorization, so the arrangement is best read as investment in readiness. Savara and PANTHERx Rare, January 2026 Form 10-K, 2025
The company’s operating leverage cuts in both directions. A successful launch would let a focused team devote resources to one indication, supplier network and specialty channel. A prolonged review leaves much of the same infrastructure with only one prospective product to serve. That is the reason to follow both the application and the expense trajectory. The amount Savara has already committed to preparation matters because the benefit of that preparation begins only when sales can start, while the costs appear in quarterly reporting today. Form 10-Q, September 2026
03 Regulatory milestones, trial estimates and financing deadlines
In its May 12 update and again on August 11, 2026, Savara said it expected a U.K. decision in the fourth quarter of 2026 and an EU decision in the first quarter of 2027. The U.K. application had been accepted for accelerated review and the European Medicines Agency had validated the EU application. The two expectations concern reviews separate from the U.S. timetable. Form 10-Q, September 2026 Savara, August 11, 2026 Q2 results Savara, Q1 2026 update on U.K. and EU regulatory timelines
An FDA approval would define the eligible population and conditions of use in the label. The approval date and terms would determine which financing conditions Savara has met. A communication establishing another action date would improve confidence in the schedule but leave those economic terms untriggered. A complete response letter would introduce a different task: establishing which changes the agency requires and whether the company can describe a credible timetable for addressing them. Savara, November 20, 2026 Form 10-Q, September 2026
A contractual deadline is a separate kind of milestone. The date belongs on a financial calendar because eligibility for the RTW payment depends on it. It does not create a regulatory due date, and an FDA action can occur outside the window. The amended Hercules facility has its own conditions and draw mechanics. Readers following the two arrangements can use chapter 10 for the specific conditions and then compare any future change with the text of that agreement. Form 10-Q, September 2026
Registry estimates are a third category. The IMPALA-2 study record includes the randomized trial and a long-term extension, so the dated completion field concerns clinical follow-up rather than an FDA decision. Publication of randomized or follow-up results can occur separately from registry completion. Regulatory timelines, financing cutoffs and trial follow-up are all material to Savara, but there is little reason for them to move together. This distinction became more important once the only specific FDA action date in the public materials ceased to be operative. ClinicalTrials.gov, NCT04544293 Savara, November 20, 2026
04 The disease: what the autoantibody does, and why the route matters
The air spaces are where the problem becomes visible. Surfactant helps regulate surface tension in the lung, and alveolar macrophages take part in clearing material from the air spaces. In autoimmune PAP, antibodies neutralize GM-CSF and interfere with the macrophages’ normal function. Surfactant can then build up, interfering with gas exchange. The target of inhaled GM-CSF is this deficit in signaling. The treatment hypothesis follows from the disease mechanism, and its clinical relevance depends on measurable improvement when patients receive the recombinant signal. Kitamura et al., Journal of Experimental Medicine 1999 McCarthy et al., AJRCCM 2022 Trapnell et al., NEJM 2025
A diagnosis of PAP describes a pattern that can have several causes. Genetic abnormalities, secondary disease and an autoimmune response can all be relevant in the broader syndrome. This is the reason Savara’s indication is framed around autoimmune PAP. The guideline describes a diagnostic sequence that can combine imaging with lavage cytology and subsequent testing of GM-CSF antibodies to establish the cause. The clinical label for any product would define its own indication, and the evidence for treating patients with confirmed autoimmune disease addresses a specific population within the wider syndrome. McCarthy et al., European Respiratory Journal 2024
The European guideline describes dyspnea and hypoxemia and recognizes that the spectrum can extend to respiratory failure. An elevated antibody measurement supports diagnosis, while the patient’s symptoms and measures of lung function inform assessment of the disease burden. A retrospective cohort also documented infections, including opportunistic infections, during follow-up. Mabo et al., Thorax 2024 In clinical practice, confirming the cause of the disease and identifying who needs active treatment are separate tasks. McCarthy et al., European Respiratory Journal 2024 McCarthy et al., AJRCCM 2022
Whole lung lavage physically removes accumulated material. It requires expertise and is a different intervention from supplying recombinant GM-CSF. The guideline places lavage and inhaled GM-CSF among the primary treatments for symptomatic or progressive autoimmune PAP, while recognizing limitations in the evidence and the importance of the patient’s situation and local resources. A drug approval would add a specifically authorized product to the applicable market. It would coexist with specialist judgment about when a patient needs a procedure and when an inhaled treatment may be appropriate. McCarthy et al., European Respiratory Journal 2024
The guideline also considers rituximab, plasmapheresis and lung transplantation in selected circumstances. Their place in that guideline reflects the serious end of a rare disease spectrum, and their evidence should be read at the level of each intervention. For a commercial reader, the relevant inference is that a single prevalence estimate covers people with very different clinical needs. An epidemiologic count is a useful population boundary, while the patients with a prescription, authorization and access to a specific product form a narrower operational group. McCarthy et al., European Respiratory Journal 2024 Inoue et al., AJRCCM 2008
05 IMPALA-2: what the numbers show, and what they do not
IMPALA-2 was the pivotal double-blind randomized study. Investigators assigned 164 patients with autoimmune PAP to once-daily inhaled molgramostim or placebo for 48 weeks, with 81 patients allocated to the active arm and 83 to placebo. The main analysis measured the change from baseline at week 24 in hemoglobin-adjusted diffusing capacity for carbon monoxide (DLCO), expressed as a percentage of the predicted value. That outcome describes the lung’s ability to transfer gas. The design provides a comparison with a control arm under the same trial conditions. Trapnell et al., NEJM 2025 ClinicalTrials.gov, NCT04544293
At week 24, the estimated mean change in DLCO was 9.8 percentage points in the molgramostim arm and 3.8 in the placebo arm. The estimated between-arm difference was 6.0 points, with a 95% confidence interval of 2.5 to 9.4 and a reported P value below 0.001. The treatment difference is the figure that reflects the randomized comparison. The placebo change is part of that interpretation, because improvements seen during a study can occur in both groups. Trapnell et al., NEJM 2025
The longer blinded comparison at week 48 also favored molgramostim on DLCO. The reported changes were 11.6 points for the treatment arm and 4.7 for placebo. At week 24, the St. George’s Respiratory Questionnaire total score improved by 11.5 points with molgramostim and 4.9 with placebo, with lower scores indicating better health status. The results therefore include improvement on both a pulmonary function measure and the prespecified total questionnaire score at their relevant visits. Trapnell et al., NEJM 2025
The secondary hierarchy sets a clear limit on how to interpret the remaining endpoints. The paper reports that the activity subscore did not differ significantly between arms at week 24, preventing formal inference for the outcomes later in the testing sequence. An estimated improvement on a later measure can still generate a hypothesis. Statistical confidence from the primary endpoint cannot simply be transferred down the list, even when a measure addresses a related aspect of disease. Trapnell et al., NEJM 2025
Adverse events and serious adverse events occurred in similar proportions across the two Phase 3 arms. That is the appropriate broad comparison for the randomized period. A trial of this size supplies less information about infrequent events and use in populations outside the enrolled group. In the earlier IMPALA trial, authors also reported broadly similar adverse-event proportions, with chest pain occurring more often in the continuous molgramostim arm. These are trial observations with distinct study populations and periods of observation. Trapnell et al., NEJM 2025 Trapnell et al., NEJM 2020
The earlier IMPALA trial used a different primary outcome: the change in the alveolar–arterial oxygen difference after 24 weeks. Investigators randomized 138 patients across continuous treatment, intermittent treatment and placebo arms. The estimated difference between continuous treatment and placebo was −5.2 mm Hg in the original full analysis set (P = 0.118). After imputation of four invalid measurements, the revised comparison was −6.2 mm Hg (P = 0.025). IMPALA and IMPALA-2 therefore offer complementary gas-exchange evidence, while their estimates are expressed in different units and address different primary tests. Trapnell et al., NEJM 2020 ClinicalTrials.gov, NCT02702180 (IMPALA)
A second randomized study, PAGE, tested intermittent inhaled sargramostim in Japanese patients with autoimmune PAP. It reported improvement in the alveolar–arterial oxygen gradient in the active group relative to placebo. Its regimen, trial population and primary endpoint differed from those of IMPALA-2. The shared result is evidence supporting inhaled GM-CSF as a treatment approach. A direct comparative judgment between regimens would require a design that evaluates them against each other under common conditions. Tazawa et al., NEJM 2019 ClinicalTrials.gov, NCT02835742 (PAGE) Trapnell et al., NEJM 2025
06 Open-label follow-up and related studies
The IMPALA-2 extension followed the blinded phase and allowed participants to receive open-label molgramostim. The longer observation period can help describe how participants fared while taking the drug and how former placebo recipients changed after crossover. Once both groups know they receive treatment and follow different treatment histories, the analysis answers a different question from the original blinded comparison. Additional follow-up is particularly relevant when a commercial product could be used beyond the duration emphasized in the pivotal trial. ClinicalTrials.gov, NCT04544293 IMPALA-2 open-label results, ATS 2026 conference abstract
Savara’s open-label results were presented in a 2026 conference supplement. Their provenance matters because a conference abstract gives a shorter account of the analyses than the full publication of the randomized phase. The open-label design is also independently important: patients’ decision to remain in follow-up, changes in their management and knowledge of treatment can matter when interpreting longitudinal outcomes. For the time being, the evidence with the clearest causal interpretation remains the randomized period of IMPALA-2. IMPALA-2 open-label results, ATS 2026 conference abstract Trapnell et al., NEJM 2025
In a separate investigator trial, Campo and colleagues randomized 18 patients after a baseline lavage. In one group patients also received inhaled sargramostim. The median time to first rescue lavage was 30 months in the treated group and 18 months in controls. The study was small and selected patients who had already undergone a procedure. It addresses whether inhaled GM-CSF can complement lavage in that particular setting. Its estimate applies to this trial of sargramostim after lavage. Campo et al., European Respiratory Journal 2024
In October 2026 Savara also disclosed a post hoc analysis of the earlier IMPALA trial in participants with mild diffusion impairment. The subgroup helps define a question about treatment earlier in the course of impairment. Subgroup selection after the primary analysis leaves more uncertainty than the prespecified randomized comparison across the enrolled population. The result applies to the mild-impairment subgroup defined within IMPALA and leaves the potential treatment population uncertain. Savara, CHEST presentation, October 2026 Trapnell et al., NEJM 2020
The randomized sargramostim and molgramostim studies together are informative for the class, while the use of lavage as an outcome varies by study. A lavage procedure depends both on the state of the patient and on decisions by clinicians and centers. That makes the pragmatic outcome valuable and also explains why different study protocols can yield results that are difficult to line up. The Campo study begins after lavage, PAGE uses an oxygen-gradient endpoint and IMPALA-2 emphasizes DLCO. Each contributes a piece of evidence of a different type. Campo et al., European Respiratory Journal 2024 Tazawa et al., NEJM 2019 Trapnell et al., NEJM 2025
For Savara, the future value of longer follow-up is whether clinicians can assess durability, adverse events and use of rescue interventions in patients receiving the proposed product. Longitudinal observations can also help distinguish maintenance among continuing participants from outcomes across all patients initially randomized. The study register is the useful place to follow the status of that program. Trial completion and publication can improve information about treatment, while the separate question of when a lawful commercial launch can begin remains with the regulators. ClinicalTrials.gov, NCT04544293 Savara, November 20, 2026
07 The regulatory record: from a refusal to file to Priority Review
The U.S. filing sequence starts with the completion of a rolling submission in March 2025. Savara received a Refusal to File letter in May 2025. In the annual report, the company explains the FDA’s questions about manufacturing and comparability and describes the work undertaken before resubmission. The procedural distinction is important: the refusal concerned taking the original submission into formal review. It belongs in the history of how the company reached the current review stage. Form 10-K, 2025
Savara resubmitted in December 2025 and used FUJIFILM Diosynth Biotechnologies as the drug-substance manufacturer for the submission. In February 2026 the FDA filed the application and granted Priority Review. Those steps put the application under substantive review. Filing acceptance can be read as procedural progress following the refusal, while approval requires the agency to complete its assessment of the product and the application. Form 10-Q, September 2026 Form 10-K, 2025
The April announcement recorded a second shift in the timeline. The company said the FDA had treated responses to information requests as a major amendment and had extended its review by three months. Savara also said at the time that the FDA’s correspondence did not cite safety, efficacy or manufacturing concerns. That description is specific to the April correspondence. It gives the context of the prior extension but cannot be used to infer a reason for the November development. Savara, April 15, 2026 Savara, November 20, 2026
On November 20 Savara reported that the FDA had communicated it would miss the November 22 PDUFA target. The release said the review was continuing and that the FDA had not communicated a revised action date. Savara, November 20, 2026
The pathway is jurisdiction-specific. Savara’s quarterly filing records validation of the EMA application in March 2026 and acceptance of the U.K. application for accelerated review in April. Those events are relevant to launches in their own jurisdictions and the company’s work with suppliers and commercial partners. As of the quarterly disclosure, U.S. review remained especially important to financing because the royalty purchase agreement names FDA approval as its condition. A decision elsewhere would be a separate development. Form 10-Q, September 2026
An eventual authorization could specify use of the medicine and device, describe the safety information and define the population for which treatment may be marketed. Any commitment to collect further data would also be relevant to launch economics and to later evidence. On a negative FDA action, the key information would be the agency’s stated basis and the sponsor’s account of the work needed to respond. Those scenarios can be evaluated when an actual agency action is disclosed. Savara, November 20, 2026 Form 10-Q, September 2026
08 Manufacturing: drug substance, finished product and device
Savara depends on contract manufacturing for the proposed product. Its annual report explains the transfer of drug-substance manufacturing to FUJIFILM Diosynth Biotechnologies and identifies other contractors involved in production and device supply. These roles cover different parts of commercialization. A sponsor needs manufacturing readiness for the active material, finished product and delivery system, and discontinuity in any one of those stages could affect availability of the package as a whole. Form 10-K, 2025
This structure makes the manufacturing transition commercially significant. A process used to make the drug substance required work to support the regulatory submission. The company describes the technology transfer from GEMA to FUJIFILM in its annual filing. A transfer is relevant to comparability because the sponsor needs to support the relationship between material from the revised process and material used to generate prior evidence. The first filing history shows why those questions can matter even after the randomized clinical study is completed. Form 10-K, 2025
The annual report describes Patheon in the finished-product arrangement and PARI in the device arrangement. The finished product and device must be available in forms that work together, and the device constitutes a commercial dependency of its own. A specialty pharmacy can handle distribution arrangements, but the channel begins with released product and a usable administration system. When assessing a launch timetable, a manufacturing step, a regulatory step and a distribution step should therefore be treated as separate dependencies. Form 10-K, 2025 Savara and PANTHERx Rare, January 2026
Contract manufacturing also determines how much of the cost base can be managed while the review continues. The SEC disclosures include commitments for manufacturing and other vendors. The quarter’s expense and cash flow measures capture different parts of those obligations as work is performed, billed and paid. A manufacturing agreement can involve spending before any product is sold, so postponement of the decision changes the period during which manufacturing and other operating costs have to be funded from existing resources. Form 10-K, 2025 Form 10-Q, September 2026
The device has an additional economic dimension. The PARI arrangement includes contingent contractual obligations, while the RTW proposal would concern a separate share of U.S. net sales. These commitments are distinct from manufacturing cost and from the cost of distribution. Before sales and related costs are reported, a total margin remains a modeling assumption. The detailed contractual disclosures give a basis for identifying the cost categories affected by approval and first commercial sale. Form 10-K, 2025 Form 10-Q, September 2026
09 Cash, burn and approval-linked capital
Savara closed September 2026 with $29.8 million of cash and equivalents and $99.8 million of short-term investments. The combined $129.6 million compares with $235.7 million at December 31, 2025. Short-term investments account for most of the reported resources, so the cash line alone gives an incomplete picture of liquidity. The combined balance is a September balance-sheet measure. It is the starting point for assessing the cash sensitivity of a longer review rather than a statement of what the company held on November 20. Form 10-Q, September 2026
Cash used in operating activities reached $105.3 million over the first nine months of 2026, up from $76.0 million for the comparable 2025 period. Subtracting the six-month operating cash use disclosed in the June filing from the nine-month figure implies about $42.5 million used in Q3. Separating Q3 from the first half helps show how recent spending differed from the year-to-date average. It also limits the risk of comparing a rolling burn number with one specific cash balance without checking what time period each represents. Form 10-Q, September 2026 Form 10-Q, June 2026
Savara reported Q3 operating expenses of $43.5 million, including $24.9 million of research and development and $18.5 million of general and administrative expense, with rounding. The net loss was $43.0 million. General and administrative expense rose 92.6% year over year. Management attributes the increase to personnel costs, including stock compensation and hiring, IT and commercial preparation. That mix shows how spending ahead of authorization extends beyond research, with a larger organization and commercial activities already present in the expense base. Form 10-Q, September 2026
The nine-month cash-flow reconciliation explains why net loss and cash consumption differ. Savara reported a $120.5 million net loss, about $10.1 million of net operating asset and liability changes that used cash, and about $25.4 million in offsetting net noncash charges. Stock compensation formed a substantial part of the noncash component. A loss measures accrual accounting performance, and a cash flow statement captures when operating resources actually leave the company. Both are relevant when the commercial start can shift without immediately changing the organization’s commitments. Form 10-Q, September 2026
The filing states that management expected the September resources to support operations for at least twelve months from the date the financial statements were issued. Using the published balances and a flat historical run rate gives different illustrations: about eleven months at the nine-month operating rate and about nine months at the third-quarter rate, measured from the September balance. This is a Merlintrader calculation using historical data. It deliberately leaves out future financing, spending changes, working-capital variation and any change in the regulatory or commercialization timetable. Form 10-Q, September 2026 Form 10-Q, June 2026
The new information makes stress testing the timing of expenditure more valuable than assigning a single date to cash exhaustion. A manufacturer payment or payroll expense can come due while the application remains under review. A later authorization could unlock some funding and alter the company’s spending needs in the same period. The next disclosures to compare with September are the combined balance, operating cash use during the next reporting period and any royalty proceeds or loan draws actually completed. Savara, November 20, 2026 Form 10-Q, September 2026
10 Debt, the royalty sale and the March 2027 deadline
The Hercules credit facility is already part of the capital structure. Savara entered the loan and security agreement in March 2025, drew the initial $30 million and subsequently amended the terms. The company’s balance sheet then reflects the funded borrowing as a liability accounting for expenses, accretion and related adjustments. The face amount originally borrowed and the carrying value at a later statement date describe the same financing from different perspectives. The additional tranches are separate from that debt. Form 10-Q, September 2026 Form 8-K, January 2026
The January amendment provides for up to $45 million in the first post-approval tranche. It permits up to $30 million in the second after full draw or expiration of the first, whichever comes earlier. Both tranches are subject to the earlier of 120 days after attainment of the approval milestone or June 30, 2027. The amendment defines the Approval Milestone to require evidence satisfactory to the agent, confirmation that no Default or Event of Default has occurred, and a label materially consistent with what Savara sought. The clock runs from that defined milestone, and June 30 can shorten the time available for borrowing. If a qualifying milestone occurs, management would still have to determine how much secured debt to take and when. Form 10-Q, September 2026 Form 8-K, January 2026 Hercules first amendment, SEC exhibit
The quarterly filing describes April 1 and September 30, 2027 as the revised dates for the minimum cash and revenue covenants, respectively, if market capitalization falls below the applicable contractual thresholds. Those dates concern existing lending terms and should be read with the agreement and its conditions. A company with meaningful liquid assets can still need to manage unrestricted cash separately because a lending covenant may impose a particular definition, threshold or test date. Available cash, covenant compliance and ability to draw additional funds are related questions with separate contractual tests. Form 10-Q, September 2026 Form 8-K, January 2026
RTW would pay $75 million at closing in exchange for a tiered royalty on U.S. net sales. Section 5.2(a) requires standard FDA marketing approval for molgramostim in autoimmune PAP by March 31, 2027. Accelerated approval falls outside that definition. The approval must remain in effect and the label must be free of boxed warnings and unexpected contraindications as defined in the agreement. The purchase is subject to the other closing conditions. RTW purchase and sale agreement, SEC exhibit Royalties begin in the calendar quarter of the first U.S. commercial sale. Base rates range from 7% in the first tier to 1% in the highest tier, with a cumulative royalty cap of $187.5 million. Because Savara had yet to receive qualifying U.S. approval by September 30, 2026, the provision that could raise the first-tier rate to 9.5% based on 2027 net sales is inapplicable. The agreement retains separate sales tests for 2028 and later years. The thresholds are redacted. RTW purchase and sale agreement, SEC exhibit Form 10-Q, September 2026
A royalty transaction can fund launch preparation without issuing shares or adding a conventional secured loan. Its cost is the specified portion of qualifying future sales, and the size and timing of that cost depend on sales performance. The deadline is also an eligibility boundary for the upfront payment. Even within the window, a narrower label could permit a launch while leaving the RTW condition unmet if the restriction falls within the contract’s definition of an unexpected contraindication. A later approval could also permit commercial activity with a different financing position. RTW purchase and sale agreement, SEC exhibit The current review has no announced replacement target against which to compare that boundary. Savara, November 20, 2026 Form 10-Q, September 2026
The two conditional sources total $150 million in nominal capacity. The RTW agreement generally requires repayment of designated secured debt at closing unless the purchaser consents. RTW agreement, Sections 5.2(b) and 6.8 Savara says an intercreditor agreement between the purchaser and the lenders allows borrowings under the amended Hercules facility to remain outstanding. Form 10-Q, September 2026 The cash available for operations would depend on whether the royalty agreement closes and how much Savara draws under the credit facility.
Reported liquidity excludes amounts that Savara could receive after qualifying approval and satisfaction of the applicable funding or draw conditions. Form 10-Q, September 2026
11 Shares, pre-funded warrants and the awards that vest partly on approval
The company reported 205,536,152 shares of common stock outstanding on September 30 and 220,623,511 on November 9. The two observations come from different parts of the quarterly report: the period-end statements and the filing cover. The earlier point is the appropriate denominator for comparisons with other September balance-sheet items. The later one is the more recent legal outstanding count disclosed on the cover. The roughly 15.1 million share difference, by itself, does not specify what instruments were exercised or what proceeds the company might have received. Form 10-Q, September 2026
A separate instrument is the pre-funded warrant. At September 30 the company reported approximately 48.6 million such warrants outstanding with a remaining exercise price of $0.001 per share. The income statement treatment reflects the nominal exercise price: qualifying pre-funded warrants are included in the weighted-average share count used in earnings per share. This is why a quarterly per-share denominator can exceed common shares legally issued at a given date. An exercise may change the share register without raising anything like the proceeds of an ordinary offering. Form 10-Q, September 2026
Equity incentive awards add another layer. The September notes show outstanding stock options, unvested restricted stock units and performance stock units. The units and options can differ in their vesting and exercise conditions, and certain performance awards are tied partly to regulatory outcomes. The resulting future share issuance has to be read instrument by instrument. Aggregating the September instruments can illustrate potential exposure, while simply adding September warrants to the November share count could double count instruments if some were exercised between the two dates. Form 10-Q, September 2026
The increase in authorized shares to 600 million and the June amendment to the equity incentive plan define capacity. Authorization permits issuance up to the relevant limit. That legal capacity can help a company respond to future financing or compensation requirements, with the actual transactions appearing later in periodic reports or securities filings. In this case the November delay makes the distinction especially practical, because the extent of future financing need depends in part on whether conditional sources become available. Form 8-K, June 2026 Form 10-Q, September 2026 Savara, November 20, 2026
Savara’s outstanding common shares and pre-funded warrants are disclosed at the same reporting date in the September 10-Q. Exercises, vesting and equity offerings can each change the share count, with financing decisions and actual issuance sometimes falling in different reporting periods. Form 10-Q, September 2026
12 Ownership, short interest and the governance record
Nasdaq publishes dated short-interest balances and corresponding volume. The October 30 settlement observation was roughly 32.3 million shares short and about 12.9 days to cover, based on reported average daily volume of roughly 2.49 million shares. Days to cover is a ratio built from volume over its reference period. It provides context for the size of reported short positions, while it cannot show the pace of covering on any future trading day. Daily trading volume would depend on the circumstances at the time. Nasdaq short interest
Short interest and share counts can also be reported on different dates. A percentage calculated with a later common count depends on the chosen denominator, and a public float percentage would require a different measure again. The raw count and settlement date are therefore preferable to treating an approximate percentage as comparable across dates. The reporting interval matters especially around company events, where changes in the regulatory calendar may occur long before a new short-interest observation is available. Nasdaq short interest Form 10-Q, September 2026 Savara, November 20, 2026
Savara lists Matthew Pauls as chair and chief executive in its quarterly filing. Robert Lutz signed the filing after adding the chief financial officer role to his operating responsibilities in July. The concentration of the business makes role clarity relevant to following regulatory disclosure, spending and financing decisions. Those disclosures are more informative about corporate action than inferring management’s intentions from the movement of a position size or the date on which a beneficial ownership notice was filed. Form 10-Q, September 2026 Form 8-K, June 2026
The June filing also reports shareholder approval of changes affecting authorized shares and the equity compensation plan. That is governance evidence with a different purpose from a company earnings release or a Schedule 13G. It documents the approval of actions shareholders voted on, with implications for flexibility under future financing conditions. Grants, exercises, new issuance and any related financing proceeds can then be checked against the statements for the periods in which they occur. Form 8-K, June 2026 Form 10-Q, September 2026
These records illuminate separate aspects of public-market exposure. The issuer’s filings describe issuance capacity and share counts, ownership schedules describe positions held by specified reporting parties and the Nasdaq series aggregates open short positions on settlement dates. None separately answers the question raised by the FDA delay. The issue for the company is financing the operating period before the next meaningful update, while the public-market data provide context about the securities through which an equity financing could be undertaken. Form 10-Q, September 2026 Polar Capital, Schedule 13G Nasdaq short interest Savara, November 20, 2026
13 Red flags and the overall assessment
Savara continues to fund operations from existing resources during the FDA review. A longer wait can reduce the cash available for launch preparation and shorten the time to meet the conditions for the royalty advance or term-loan draws. Savara, November 20, 2026 Form 10-Q, September 2026 Trapnell et al., NEJM 2025
A second risk follows from how that uncertain period is financed. Savara entered the review with a pre-revenue cost base and an existing secured loan. Conditional capacity only becomes useful when the relevant event occurs and the contractual tests are satisfied. The calendar could therefore produce outcomes with differing implications for liquidity even if the drug ultimately receives an authorization. Tracking the contract dates separately from any FDA timeline prevents an eventual positive clinical or regulatory development from being translated prematurely into cash. Form 10-Q, September 2026
The organization has committed resources to supplier and launch readiness before the first sale. Some of that preparation is needed to be able to move promptly after approval, and a decision to slow spending might affect preparedness. Maintaining the same effort while review continues would use more resources before commercial activity begins. This tension is visible in the increase in general and administrative expense and in the operating cash flow reconciliation, which provide two ways to see how much effort is already being financed. Form 10-Q, September 2026 Form 10-K, 2025
Supply is another form of concentration. The proposed product relies on a drug substance, a finished formulation and a dedicated device, and Savara works with third parties in those roles. Readiness at one stage of the supply arrangement does not secure finished availability by itself. The annual filing’s manufacturing and risk discussion puts supply dependencies alongside the FDA review history. If product eventually becomes available, the pace of manufacturing, shipment and patient access would provide a practical test of whether the preparations translate into a launch. Form 10-K, 2025 Savara and PANTHERx Rare, January 2026
Commercial potential also depends on how the research population maps onto actual clinical practice. The published pivotal results support an effect on gas transfer in the studied population. Treating clinicians and payers would work from an approved label and available clinical evidence, with individual need, access and persistence affecting product use. This is a market where the number of identified patients can differ meaningfully from the number treated in any quarter, and where the use of an alternative procedure varies across patients. Trapnell et al., NEJM 2025 McCarthy et al., European Respiratory Journal 2024
A further financial risk is that an apparently sufficient combination of cash and credit can conceal a mismatch in timing. Funds may be available subject to a deadline and at a cost, while payroll and vendor expenditures arrive on a different schedule. Qualifying approval could satisfy one condition while payroll and vendor costs continue before closing or a loan draw. Form 10-Q, September 2026
The assessment turns on two upcoming types of evidence. Regulatory disclosure could clarify the schedule or outcome for molgramostim. A later financial filing could establish how much cash Savara used while awaiting that disclosure and what it did to address the wait. An update in one can change the interpretation of the other. A favorable action within the contractual window would move the focus to label, receipts and launch. A longer wait would increase the weight placed on resource management and the terms of any additional financing. Savara, November 20, 2026 Form 10-Q, September 2026
Merlintrader Health Score · $SVRA
2.75out of 5
Assessed November 20, 2026. Weighted calculation: 2.5 × 30% + 3.0 × 30% + 2.5 × 20% + 3.0 × 10% + 3.0 × 10% = 2.75. The score describes financial and operational robustness over twelve to eighteen months.
Red flags
- On November 20, Savara said the FDA would miss its November 22 target and had given no replacement date. Savara, November 20, 2026
- The RTW advance depends on qualifying FDA approval by March 31, 2027 and the other closing conditions described in chapter 10. Form 10-Q, September 2026
- The wait is funded from liquid resources while operating activities consume cash. Form 10-Q, September 2026
- Commercial preparation contributed to the higher general and administrative expense before the first sale. Form 10-Q, September 2026
- The FDA refused to file the original submission in 2025 and later extended review of the resubmitted application. Form 10-K, 2025 Savara, April 15, 2026
- Savara relies on vendors for the drug substance, finished product and delivery device. Form 10-K, 2025
- The device agreement and prospective RTW royalty have separate economic obligations. Form 10-K, 2025 Form 10-Q, September 2026
- The Hercules facility already carries secured debt and has covenants with stated start dates. Form 10-Q, September 2026
- The September warrant and equity-award balances need to be reconciled with the latest outstanding common stock count. Form 10-Q, September 2026
- Settlement-date short interest was approximately 32.3 million shares on October 30. Nasdaq short interest
SVRA Stock FAQ: Savara Questions Answered
When is the next SVRA stock catalyst?
As of November 20, 2026, the next U.S. catalyst for SVRA is an undated FDA update. Savara said the agency would miss the November 22 PDUFA target for molgramostim. The review continues without a replacement date. Savara, November 20, 2026
What is the FDA reviewing, and what has it already said?
As of November 20, 2026, the FDA is still reviewing Savara’s application for molgramostim inhalation solution in autoimmune PAP. Savara said the FDA would miss its November 22 target and had given no replacement date. The FDA had accepted the resubmission for Priority Review in February 2026. Savara, November 20, 2026 Form 10-Q, September 2026
What does Savara do?
As of September 30, 2026, Savara’s sole clinical program was molgramostim, an investigational inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis. MOLBREEVI is the proposed brand name. Form 10-Q, September 2026
How much cash does Savara have, and how long will it last?
Savara held $129.6 million in cash and short-term investments on September 30, 2026. Management expected the resources to fund operations for at least twelve months from the date the financial statements were issued. At the nine-month historical operating cash-use rate, the balance represented roughly eleven months from September 30, a Merlintrader calculation. Form 10-Q, September 2026
When does Savara report earnings, and what did the last quarter show?
Savara reported its September quarter on November 9, 2026, with $43.5 million of operating expenses and a $43.0 million net loss. As of November 20, 2026, Savara had given no date for its next periodic results. Form 10-Q, September 2026
Is SVRA at risk of dilution?
As of November 9, 2026, Savara reported 220.6 million shares outstanding. The September filing also reports pre-funded warrants and stock awards, which may add to the common share count. A potential equity financing would depend on future funding needs and financing choices. Form 10-Q, September 2026
How is Savara paying for the launch?
As of November 20, 2026, Savara had two sources of conditional capital. The $75 million RTW advance requires qualifying FDA approval by March 31, 2027 and the other closing conditions described in chapter 10. Up to $75 million of Hercules loans is subject to a separate approval milestone and draw period. Savara, November 20, 2026 Form 10-Q, September 2026
Primary sources
- Savara, November 20, 2026
- Form 10-Q, September 2026
- Form 10-K, 2025
- Savara, April 15, 2026
- Savara, August 11, 2026 Q2 results
- Savara and PANTHERx Rare, January 2026
- Form 8-K, January 2026
- Form 8-K, June 2026
- Polar Capital, Schedule 13G
- ClinicalTrials.gov, NCT04544293
- Nasdaq short interest
- Trapnell et al., NEJM 2025
- Trapnell et al., NEJM 2020
- Tazawa et al., NEJM 2019
- McCarthy et al., European Respiratory Journal 2024
- McCarthy et al., AJRCCM 2022
- Inoue et al., AJRCCM 2008
- Campo et al., European Respiratory Journal 2024
- IMPALA-2 open-label results, ATS 2026 conference abstract
- Savara, CHEST presentation, October 2026
- Form 10-Q, June 2026
- RTW purchase and sale agreement, SEC exhibit
- Savara, July 2026 patent announcement
- Form 8-K, March 2026 headquarters lease
- Savara corporate overview, January 2026 SEC exhibit
- Hercules first amendment, SEC exhibit
- Kitamura et al., Journal of Experimental Medicine 1999
- Mabo et al., Thorax 2024
- ClinicalTrials.gov, NCT02702180 (IMPALA)
- ClinicalTrials.gov, NCT02835742 (PAGE)
- Savara, ERS congress update, August 2026
- Savara, Q1 2026 update on U.K. and EU regulatory timelines
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SVRA or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, peer-reviewed publications and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Single-asset biotechnology companies carry high clinical, regulatory and financial risk. A marketing application can be refused, delayed or approved with restrictions; a launch can cost more than the capital arranged for it; and companies that spend ahead of revenue frequently raise equity at whatever price the market will bear. This company reported no revenue and a net loss of $43.0 million in the September 2026 quarter, held $129.6 million of cash and short-term investments at September 30, 2026, and depends on a qualifying FDA approval and separate financing conditions to access up to $150 million of conditional launch funding. Form 10-Q, September 2026. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



